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Background: After the clinical impact of the A(H1N1) pdm09 virus was considered to be mild, treatment with
antiviral drugs was recommended only to patients who were at risk for severe disease or who had a complicated
course of influenza. We investigated to what extent antiviral prescriptions in primary care practices were in
accordance with the recommendations, what proportion of patients diagnosed with influenza had been prescribed
antiviral drugs, and to what extent prescriptions related to the stated indications for antiviral treatment.
Methods: We used data from routine electronic medical records of practices participating in the Netherlands
Information Network of General Practice LINH in the period August - December 2009. We considered patient and
practice characteristics, clinical diagnoses and drug prescriptions of all patients who contacted their general
practitioner in the given period and who had been prescribed antiviral medication (n = 351) or were diagnosed
with influenza (n = 3293).
Results: Of all antiviral prescriptions, 69% were in accordance with the recommendations. Only 5% of patients
diagnosed with influenza were prescribed antiviral drugs. This percentage increased to 12% among influenza
patients belonging to the designated high risk groups. On the other hand, 2.5% of influenza patients not at high
risk of complications received antiviral treatment. In addition to the established high risk factors, the total number
of drug prescriptions for a patient in this year was a determinant of antiviral prescriptions. Information on time
since onset of symptoms and the clinical presentation of patients was not available.
Conclusions: General practitioners in the Netherlands have been restrictive in prescribing antiviral drugs during the
influenza pandemic, even when patients met the criteria for antiviral treatment.
Keywords: Drug prescriptions, General practice, Influenza, Human, Antivirals, Pandemics, Practice guidelines as topicBackground
On April 30th 2009, the first case of influenza A(H1N1)
pdm09 was identified in the Netherlands, while it even-
tually caused an epidemic with influenza activity above
baseline in the period 12 October through 13 December
2009 (fall season in the northern hemisphere) [1].* Correspondence: m.hooiveld@nivel.nl
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reproduction in any medium, provided the orDuring the emerging pandemic, all patients suspected
of influenza were indicated for treatment with antiviral
drugs and their relatives (household contacts) were eli-
gible for prophylactic antiviral drug use. Antiviral drugs
were sufficiently available from the national stockpile
that has been established since the H5N1 outbreak in
2003. In the beginning of August 2009, the Health
Council of the Netherlands and the National Institute
for Public Health and the Environment (RIVM) con-
cluded, in concordance with WHO recommendations
[2], that the impact of the H1N1 virus on morbidity andal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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virus, based on its so far documented relatively mild
course [3,4]. Treatment with antiviral drugs was now only
recommended for patients at risk for severe disease and
patients having a complicated course of influenza [5].
Prophylactic prescriptions were no longer recommended.
High risk patients were defined as the same patients eli-
gible for seasonal influenza vaccination, i.e. all patients of
60 years or above and patients with certain medical condi-
tions [5,6]. In addition to that, children under two years of
age, pregnant women in their third trimester, and patients
having symptoms of influenza in whom the infection oc-
curred to be unusually severe or with complications were
considered [5]. In the Netherlands, oseltamivir was the
drug of first choice for treatment of high risk patients
suspected of influenza during the pandemic. Treatment
with zanamivir was reserved for patients suspected for
an infection with a resistant influenza virus. Oseltamivir
was only available as a prescription drug, not over the
counter, and it was in stock for approximately one third
of the Dutch population (5 million doses for 16 million
inhabitants).
In view of future epidemics, it is important to evaluate the
implementation of and compliance to the recommended
guidelines. The general aim of this study was therefore to in-
vestigate whether the prescription of oseltamivir by general
practitioners (GPs) in the Netherlands was in accordance
with the national guidelines described above. We used data
from a large national database to estimate 1) the proportion
of patients receiving oseltamivir according to the guide-
lines in relation to patients’ and practices’ characteris-
tics, and 2) what proportion of patients diagnosed with
influenza received oseltamivir and which factors deter-
mined this prescription.
Methods
Practices and patients selection
Data for this study were derived from the routine elec-
tronic medical records of GP practices that participate
in the Netherlands Information Network of General
Practice (LINH), a national network of around 90 gen-
eral practices, who are representative of all Dutch gen-
eral practices with respect to geographical distribution
and degree of urbanization [7]. All Dutch citizens are
enlisted as patients in a family practice, so the popula-
tion listed in a general practice can be used as the de-
nominator in epidemiological studies. The GP is the first
professional to contact for health problems and a refer-
ral to the secondary health care system (hospitals and
medical specialists) can only be made by the GP. The
LINH practice population consists of more than 350,000
registered patients, representative of the Dutch population
with respect to age and gender. The database holds longi-
tudinal data on morbidity, prescriptions and referrals.Clinical diagnoses are coded using the ICPC (Inter-
national Classification of Primary Care) coding system
[8]. Drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) classification [9]. GP
practices were included when they provided data on the
registration of claimed services, ICPC-coded diagnoses,
and ATC-coded prescriptions for the full calendar year
of 2009. Only patients enlisted with the general practice
during the whole year 2009 were included. Data collec-
tion within the LINH network is carried our according
to Dutch legislation on privacy. Each patient is coded
with an anonymous administrative number. The key to
this coding number is only with the general practitioner.
The privacy regulation of the LINH network was approved
by the Dutch Data Protection Authority. According to the
Dutch Central Committee on Research Involving Human
Subjects, obtaining informed consent is not obligatory for
observational studies and approval by the Medical Ethical
Committee was not necessary.
Data collection
All contacts (claims) of patients with the GPs were consid-
ered. First, patients having a prescription of oseltamivir
(ATC-code J05AH02) between August 8 and December 31,
2009 were considered. No prescriptions of zanamivir were
registered. When there was more than one oseltamivir pre-
scription, only the first one was taken into account. We
looked for all diagnoses within 7 days before or after the
date of prescription, in order to take into account registra-
tion delays. However, in 88% of oseltamivir prescriptions,
the diagnosis was registered at the same day. We spe-
cifically considered diagnoses of influenza (ICPC-code
R80, which will be used by GPs for patients with
influenza-like illness in the context of an influenza epi-
demic, or upon virological confirmation of an influenza
virus), another acute respiratory infection (ARI, defined
by ICPC-codes R74 - acute upper respiratory infection,
R78 - acute bronchitis/bronchiolitis or R81 - pneumonia),
and non-specified virus infection (A77, which can be used
by GPs for patients with influenza-like illness outside the
influenza season).
Patients who did not receive oseltamivir were evaluated
for a diagnosis of influenza. When more than one episode
was present, the date of the first consultation was taken.
Recommended treatment of high risk patients with
oseltamivir was based on age (<2 years or ≥60 years), co-
morbidity (cardiac disease, respiratory disease, diabetes
mellitus, chronic renal insufficiency, reduced resistance
against infections and children up to 18 years using salicy-
lates), a complicated course of illness (the occurrence of
pneumonia within 7 days before or after the diagnosis of
influenza or ARI, or the need to prescribe antibiotics –
not for urinary infections – within these days), or a third
trimester pregnancy (an oseltamivir prescription or an
Table 1 Characteristics of 241 patients at high risk of




High risk group description
Age only 53 (22.0)
Co-morbidity only 101 (41.9)
Complicated course of illness only 13 (5.4)
Age and co-morbidity 49 (20.3)
Age and complicated course of illness 2 (0.8)
Co-morbidity and complicated course 15 (6.2)
Age, co-morbidity and complicated course 8 (3.3)
Specific co-morbidity at risk for complications*
Cardiac disease 60 (24.9)
Respiratory disease 106 (44.0)
Diabetes mellitus 27 (11.2)
Chronic renal insufficiency 5 (2.1)
Reduced resistance against infections 24 (10.0)
Children using salicylates 1 (0.4)
Third trimester of pregnancy 3 (1.2)
*Numbers add up above 100% because of multiple co-morbidities per patient.
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contact related to pregnancy, based on the assumption
that pregnant women usually have their first pregnancy-
related contact with their GP between weeks 6 and 20; a
contact indicating the birth of a child had to be no more
than 14 weeks after oseltamivir prescription or influenza
diagnosis). Details on ICPC- and ATC-codes used to clas-
sify high-risk patients have been published elsewhere [10].
Additional patient characteristics comprised gender,
month of prescribing, total number of contacts with the
practice in 2009, and the total number of prescriptions
in 2009 besides oseltamivir. Other underlying chronic
health conditions were based on a selection of diseases
with a high prevalence, a long-term course and a serious
illness, as used in the National Public Health Compass
(www.nationaalkompas.nl). This selection is based on the
list of chronic conditions from the Australian Family
Medicine Research Centre (www.fmrc.org.au) and adapted
from ICPC-2 to ICPC-1. Practice characteristics included
practice type, dispensing practice, and level of urbanisa-
tion and geographic region of the practice location.
Statistical analysis
In the group of patients with a diagnosis of influenza,
we evaluated the proportion of patients whom had been
prescribed oseltamivir and whom should have been pre-
scribed it. Univariate logistic regression analyses were
performed on the association between the prescription
of oseltamivir and a recommendation for a prescription,
as well as other patients’ and practices’ characteristics.
Multivariable regression analyses were performed to as-
sess potential determinants independently associated
with the prescription of oseltamivir. Likewise, we evalu-
ated whether oseltamivir was prescribed according to
the guidelines among all patients receiving oseltamivir.
Because of the recommendation to prescribe oseltamivir
to both very young (under two years of age) and old
(60 years or above) patients, we added age-squared in
the multivariable models to take into account the u-
shaped association when using the continuous age vari-
able. Only variables that significantly improved the model
fit, based on Likelihood-ratio tests (p-value < 0.05), were
included. Since patients were clustered within practices,
we used multilevel logistic regression. All analyses were
performed in Stata version 11.2 (StataCorp LP, College
Station, TX, USA).
Results
We included 68 GP practices with complete and reliable
data records for the year 2009. Twelve patients with
missing age were excluded, leaving 260,298 enlisted pa-
tients for analyses (1.6% of the Dutch population). Of all
patients, 351 (1.4 per 1,000 enlisted patients) had been
prescribed oseltamivir. The total number of oseltamivirprescriptions ranged between practices from 0 (11 prac-
tices) to 10.7 prescriptions per 1000 enlisted patients
(right-skewed distribution; geometric mean = 0.9; geo-
metric standard distribution = 3.4).
Half of the patients receiving oseltamivir had a diagno-
sis of influenza (n = 181; 51.6%). The most frequently
registered diagnoses in 105 patients not having influ-
enza, ARI or a non-specified viral infection were general
disease (21 patients), fever (17 patients), other viral dis-
ease (12 patients), and ‘no disease’ (11 patients). No valid
ICPC-code was recorded for 23 patients (6.6%). Of all
oseltamivir prescriptions, 241 (68.7%) were to patients
belonging to the designated high risk groups. Table 1
shows the distribution of the underlying reasons for
qualification for oseltamivir in these patients.
Table 2 shows factors that independently influenced
a prescription according to clinical guidelines among
all patients who had been prescribed oseltamivir. As
expected, both a very young and a higher age were
associated with an increased chance of having an
oseltamivir prescription according to the recommenda-
tions. Independently of age, a higher number of contacts
with the GP and a higher number of prescriptions in gen-
eral were positively associated with prescribing oseltamivir
according to the guidelines.
A total of 3,293 patients (1.3% of the study population)
were diagnosed with influenza and oseltamivir was pre-
scribed to 181 (5.5%). The weekly number of influenza
Table 2 Factors influencing a prescription of oseltamivir






Variable OR (95% CI) OR (95% CI) P-value
Age at prescription
(continuous)
0.87 (0.83 to 0.91) 0.84 (0.80 to 0.90) <0.001
Age-squared 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) <0.001
Number of contacts
with GP in 2009
<6 ref - ref -
6 or more 3.00 (1.87 to 4.82) 2.19 (1.18 to 4.08) 0.014
Total number of
prescriptions in 2009*
<8 ref - ref -
8 or more 4.60 (2.80 to 7.57) 3.24 (1.63 to 6.42) 0.001
GP = general practitioner; OR = odds ratio; CI = confidence interval.
*Excluding oseltamivir prescriptions.
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Dutch influenza-like illness (IAZ) surveillance (data not
shown) [1]. Of all influenza patients, 1,051 (31.9%)
belonged to the designated high risk groups, of whom
126 (12.0%) indeed received oseltamivir. This percentage
varied from 9.5% (n = 16) among children aged 2 to
14 years to 18.0% (n = 18) among children under two
years of age. On the other hand, 2,242 patients diag-
nosed with influenza did not belong to the high risk
groups and yet 55 (2.5%) received a prescription of
oseltamivir.
Univariate analyses showed that age, underlying co-
morbidity, the total number of contacts with the GP in
2009 and the total number of prescriptions in 2009 were
determinants of the prescription of oseltamivir among
influenza patients (Table 3). Patients with underlying co-
morbidity had the highest chance of an oseltamivir pre-
scription. All of the designated high risk groups were
statistically significantly associated with oseltamivir pre-
scription, except children receiving chronic aspirin ther-
apy. Taking into account specific medical conditions
showed that patients with respiratory diseases and preg-
nant women had a higher chance of treatment, while no
associations were observed for other underlying diseases.
Ten percent of all influenza patients had a complicated
course of illness, but this was not associated with
oseltamivir treatment. Practice characteristics were not
associated with oseltamivir prescriptions.
The results of the multilevel model with age, co-
morbidity, complicated course of illness and number of
prescriptions, are presented in Table 3 as well. After ad-
justment for other factors, an age of 60 years or above in
itself was not associated with oseltamivir prescription.Independently of a high risk for severe disease due to
age, co-morbidity or a complicated course of illness, the
total number of drug prescriptions was positively associ-
ated with the prescription of oseltamivir.
Among influenza patients who did not belong to the
designated high risk groups, chronic health conditions
other than those at high risk of severe illness were not
associated with oseltamivir prescription, nor were age,
gender, and consultation rate or practice characteristics
(Table 4). The only significant determinant for oseltamivir
prescriptions was the total number of drug prescriptions
in 2009. The odds ratio for drug prescriptions did not
change in the multilevel logistic model (OR = 2.28; 95%
CI = 1.20 to 4.32).
Discussion
This study showed that general practitioners in the
Netherlands have been restrained in prescribing oseltamivir
during the influenza pandemic. Only 5% of all patients
diagnosed with influenza were prescribed oseltamivir,
and only 12% of those who were at high risk of severe
illness. On the other hand, when GPs have prescribed
oseltamivir, they have rather well followed the recom-
mendations in the national guidelines. Only 2.5% of in-
fluenza patients not at high risk were prescribed
oseltamivir, and of all antiviral drugs prescribed, 69%
were for patients at high risk for severe disease. The
total number of drug prescriptions in 2009 and the
total number of GP consultations, which can be consid-
ered proxies for underlying morbidity, were determi-
nants for oseltamivir prescription in addition to the
high risk factors of co-morbidity, a very young or an
older age.
Strengths and limitations of this study
This study was conducted using a large database of pa-
tients, representative for the general Dutch population,
providing a complete picture of morbidity and prescrip-
tions. A limitation of this study was the lacking informa-
tion on specific details on presented symptoms. More
severely ill patients could have been hospitalized, but in-
formation on care provided outside the general practice
was lacking in our data. This could have resulted in an
underestimation in the number of patients with a more
severe illness, causing a negative association with the
prescription of oseltamivir.
Co-morbidity at high risk of complications was defined
by ICPC- and ATC-codes that are used in general prac-
tices to select patients eligible for influenza vaccination
[10,11]. This method has been used to monitor the
Dutch influenza vaccination rate in different high risk
groups for several years, using the LINH database, with
stable and representative results [12,13]. We assumed
these patients had at least one contact (claim) with their
Table 3 Potential factors influencing the prescription of oseltamivir by general practitioners to 3,293 influenza patients
Prescription of oseltamivir, n of
patients (%)
Univariate analysis Adjusted multilevel analysis
Variable No Yes OR (95% CI) OR (95% CI)
Gender (not in model)
Male 1,477 (47.5) 88 (48.6) ref -
Female 1,635 (52.5) 93 (51.4) 0.94 (0.70 to 1.28)
Age at diagnosis
< 2 yrs 82 (2.6) 18 (9.9) 3.62 (2.07 to 6.36) 5.71 (3.01 to 10.80)
2 to 14 yrs 972 (31.2) 32 (17.8) 0.54 (0.36 to 0.83) 0.70 (0.44 to 1.11)
15 to 24 yrs 469 (15.1) 20 (11.0) 0.70 (0.43 to 1.16) 0.88 (0.51 to 1.52)
25 to 59 yrs 1,321 (42.4) 80 (44.2) ref - ref -
60 yrs or older 268 (8.6) 31 (17.1) 1.84 (1.19 to 2.87) 0.96 (0.58 to 1.57)
Co-morbidity at risk for complications
No 2,562 (82.3) 89 (49.2) ref - ref -
Yes 550 (17.7) 92 (50.8) 4.82 (3.53 to 6.57) 4.94 (3.29 to 7.40)
Number of co-morbidities at risk (not in model)
0 2,562 (82.3) 89 (49.2) ref -
1 443 (14.2) 70 (38.7) 4.55 (3.27 to 6.32)
2 or 3 107 (3.4) 22 (12.1) 5.92 (3.57 to 9.81)
Specific co-morbidity at risk for complications* (not in model)
Cardiac disease 178 (5.7) 28 (15.6) 3.04 (1.97 to 4.68)
Respiratory disease 290 (9.3) 54 (30.0) 4.17 (2.95 to 5.89)
Diabetes mellitus 112 (3.6) 17 (9.4) 2.79 (1.64 to 4.77)
Chronic renal insufficiency 9 (0.3) 3 (1.7) 5.84 (1.57 to 21.82)
Reduced resistance against infections 59 (1.9) 9 (5.0) 2.72 (1.33 to 5.59)
Children using salicylates 13 (0.4) 1 (0.6) 1.33 (0.17 to 10.24)
Third trimester of pregnancy 12 (0.4) 3 (1.7) 4.38 (1.22 to 15.68)
Complicated course of illness
No 2,810 (90.3) 159 (87.8) ref - ref -
Yes 302 (9.7) 22 (12.2) 1.29 (0.81 to 2.04) 0.95 (0.57 to 1.58)
Contacts with GP in 2009 - (not in model)
<6 1,850 (59.4) 86 (47.5) ref
6 or more 1,262 (40.6) 95 (52.5) 1.62 (1.20 to 2.19)
Prescriptions in 2009 †
<8 2,300 (73.9) 92 (50.8) ref - ref -
8 or more 812 (26.1) 89 (49.2) 2.74 (2.03 to 3.71) 1.36 (0.89 to 2.09)
GP = general practitioner; OR = odds ratio; CI = confidence interval.
*Reference group does not have the specific co-morbidity.
†Excluding oseltamivir prescriptions.
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codes. We think it is very unlikely that a patient with a
certain chronic condition did not contact his or her gen-
eral practitioner for an entire year, nor was prescribed
any medication for this chronic condition during that
year. Misclassification of patients with co-morbidity is
therefore unlikely.Comparison with other studies
Our observations are in line with those from Fietjé and col-
leagues [14], who found that 85% of Dutch patients with an
oseltamivir prescription belonged to the high risk groups.
Their study was based on telephone interviews with pa-
tients who filled a prescription for oseltamivir through
community pharmacists. Results from other countries on
Table 4 Potential factors influencing the prescription of oseltamivir to 2,242 influenza patients not at high risk
Prescription of oseltamivir, n of patients (%) Univariate analysis
Variable No Yes OR (95% CI)
Patient characteristics
Gender
Male 1,039 (47.5) 29 (52.7) ref -
Female 1,148 (52.5) 26 (47.3) 0.81 (0.47 to 1.39)
Age at diagnosis
2 to 14 yrs 819 (37.4) 16 (29.1) 0.69 (0.37 to 1.29)
15 to 24 yrs 411 (18.8) 12 (21.8) 1.03 (0.52 to 2.06)
25 to 59 yrs 957 (43.8) 27 (49.1) ref -
Chronic health condition not at high risk
No 1,754 (80.2) 45 (81.8) ref -
Yes 433 (19.8) 10 (18.2) 0.90 (0.45 to 1.80)
Number of contacts with GP in 2009
<6 1,468 (67.1) 36 (65.5) ref -
6 or more 719 (32.9) 19 (34.5) 1.08 (0.61 to 1.89)
Total number of prescriptions in 2009*
<8 1,888 (86.3) 41 (74.5) ref -
8 or more 299 (13.7) 14 (25.5) 2.16 (1.16 to 4.00)
Practice characteristics
Type of practice
Solo practice 706 (32.3) 24 (43.6) ref -
Duo practice 437 (20.0) 8 (14.6) 0.54 (0.24 to 1.21)
Group practice 1,044 (47.7) 23 (41.8) 0.65 (0.36 to 1.16)
Dispensing practice 101 (4.6) 2 (3.6) 0.78 (0.19 to 3.24)
Urbanicity practice location
(Very) strongly urban 1,116 (51.0) 27 (49.1) 0.84 (0.42 to 1.68)
Moderately urban 418 (19.1) 12 (21.8) ref -
Mildly/not urban 653 (29.9) 16 (29.1) 0.85 (0.40 to 1.82)
GP = general practitioner; OR = odds ratio; CI = confidence interval.
*Excluding oseltamivir prescriptions.
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pandemic are scarce. In a study by Hersh and col-
leagues, antivirals were prescribed in 58% of influenza
visits to US ambulatory physicians [15]. The prescrip-
tion rate for patients younger than 2 years was 47% and
68% for patients 65 years or older. Information on
underlying medical conditions was not available. A
study from the UK focusing on 90 pregnant women pre-
senting with influenza-like illness in primary care, 61%
were prescribed antiviral drugs [16]. Forty-three women
were in their third trimester, of whom 26 (60%) received
antivirals. In a Chicago hospital, 65% of high-risk patients
with influenza-like illness received oseltamivir treatment
[17]. These figures are much higher than in our study.
The results of our study show that if oseltamivir was
prescribed, it was in accordance with the guidelines inmost cases. A study by Grol et al. showed that compli-
ance to guidelines was rather good in Dutch primary
care; recommendations were followed in, on average,
61% of the decisions [18]. Based on our research it can
therefore be said that when general practitioners in the
Netherlands prescribed oseltamivir, they followed the
recommendations on the prescribing fairly well. But they
often did not prescribe, even when oseltamivir was
recommended. The availability of antiviral drugs was no
problem, since they were available from the national
stockpile.
A possible explanation for withholding oseltamivir to
patients at higher risk of complications might have been
a late presentation of the patient. From the Dutch
influenza-like illness surveillance we know that patients
wait on average 3 days before contacting a doctor for
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viral drugs should start preferably within 48 hours of the
onset of illness. We had no information on time since
onset of symptoms, but awareness and anxiety about the
on-going pandemic may have urged patients to contact
their GP earlier than usually.
Conclusions
In conclusion, this study showed that general practitioners
in the Netherlands have been very restrained in prescribing
antiviral drugs during the influenza pandemic. Where GPs
have used antiviral medication, they have rather well
followed the recommendations in the national guidelines.
To our knowledge, this is the first study in which recom-
mendations for prescribing oseltamivir in primary care has
been evaluated in detail. More information is needed on
the reasons for underuse of antiviral drugs in patients be-
longing to the designated high risk groups. We believe it is
important to evaluate the implementation of recommended
guidelines. In this way, in the case of future epidemics, the
recommendations may be adjusted and can be applied even
more effectively.
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